ESMO 2020

Enfortumab vedotin | Urothelial Cancer | Abstract 2223

EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors

Enfortumab vedotin | Urothelial Cancer | Abstract 2065

Study EV-302: A 3-arm, open-label, randomized phase 3 study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer

Tucatinib | Breast Cancer | Abstract 2073

Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and brain metastases

Tucatinib | Colorectal Cancer | Abstract 2070

MOUNTAINEER: Open-Label, Phase 2 Study of Tucatinib Combined with Trastuzumab for HER2-Positive Metastatic Colorectal Cancer

Tucatinib | Breast Cancer | Abstract 2068

HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer

Tucatinib | Research | Absract 3068

Physiologically Based Pharmacokinetic (PBPK) Modeling of the Central Nervous System (CNS) Pharmacokinetics of Tucatinib in Patients with Breast Cancer Brain Metastasis

Tisotumab vedotin | Ovarian Cancer | Abstract 2221

innovaTV 208: New Weekly Dosing Cohort in the Phase 2 Study of Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer

Ladiratuzumab vedotin | Breast Cancer | Abstract 2075

SGNLVA-002: Single arm, open-label, phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

Tucatinib | Breast Cancer | Abstract 2067

Impact of Tucatinib on Health-Related Quality of Life (HRQoL) in Patients with HER2+ Metastatic Breast Cancer (MBC) with and without Brain Metastases (BM)

Tisotumab vedotin | Cervical Cancer | Abstract 3435

Tisotumab vedotin (TV) in previously treated recurrent or metastatic cervical cancer (r/mCC): results from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study